

Ildiko Lingvay

List of Publications by Citations

Source: <https://exaly.com/author-pdf/960210/ildiko-lingvay-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

7,460
citations

34
h-index

86
g-index

127
ext. papers

10,452
ext. citations

10.6
avg, IF

6.2
L-index

#	Paper	IF	Citations
108	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 1834-1844	59.2	2547
107	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 841-851	59.2	567
106	Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. <i>Circulation</i> , 2007 , 116, 1170-5	16.7	458
105	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021 , 384, 989	59.2	351
104	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 275-286	18.1	270
103	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. <i>Diabetes Care</i> , 2018 , 41, 258-266	14.6	208
102	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <i>Lancet, The</i> , 2019 , 394, 39-50	40	186
101	Noninvasive quantification of pancreatic fat in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4070-6	5.6	144
100	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 898-907	27.4	138
99	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. <i>Diabetes Care</i> , 2019 , 42, 2272-2281	14.6	128
98	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2291-2301	5.6	125
97	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 889-897	6.7	114
96	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1403-1413	27.4	113
95	Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 971-984	40	109
94	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1414-1425	27.4	102
93	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 382, 2493-2503	59.2	100
92	Pancreatic steatosis and its relationship to β cell dysfunction in humans: racial and ethnic variations. <i>Diabetes Care</i> , 2012 , 35, 2377-83	14.6	85

91	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019 , 42, 2262-2271	14.6	82
90	Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery?. <i>Diabetes Care</i> , 2013 , 36, 2741-7	14.6	82
89	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 834-844	18.1	81
88	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). <i>Journal of the Endocrine Society</i> , 2021 , 5, A10-A10	0.4	78
87	Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4). <i>Journal of the Endocrine Society</i> , 2021 , 5, A63-A64	0.4	78
86	Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2). <i>Journal of the Endocrine Society</i> , 2021 , 5, A10-A11	0.4	78
85	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. <i>Obesity</i> , 2020 , 28, 1050-1061	8	77
84	β-cell function preservation after 3.5 years of intensive diabetes therapy. <i>Diabetes Care</i> , 2012 , 35, 1406-1414	14.6	73
83	Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?. <i>Diabetes Care</i> , 2009 , 32, 1789-95	14.6	67
82	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <i>Diabetes and Metabolism</i> , 2019 , 45, 409-418	5.4	54
81	Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. <i>Journal of Investigative Medicine</i> , 2007 , 55, 230-6	2.9	53
80	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020 , 229, 61-69	4.9	53
79	Hyposialylated IgG activates endothelial IgG receptor FcβRIIB to promote obesity-induced insulin resistance. <i>Journal of Clinical Investigation</i> , 2018 , 128, 309-322	15.9	52
78	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 442-451	6.7	44
77	Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. <i>Journal of Investigative Medicine</i> , 2013 , 61, 40-4	2.9	36
76	Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2007 , 21, 137-42	3.2	36
75	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , 2018 , 41, 1926-1937	14.6	34
74	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019 , 18, 73	8.7	33

73	Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 321-8	2.5	33
72	Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 734-44	7.5	29
71	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019 , 42, 1454-1463	14.6	28
70	Effect of Adding Liraglutide vs Placebo to a High-Dose Insulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2016 , 176, 939-47	11.5	25
69	Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. <i>Journal of Investigative Medicine</i> , 2007 , 55, 62-8	2.9	24
68	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. <i>Lancet, The</i> , 2021 ,	4.0	22
67	Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 4449-4458	5.6	21
66	Random blood glucose: a robust risk factor for type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1503-10	5.6	19
65	Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1798-806	5.6	18
64	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. <i>Journal of Medical Virology</i> , 2021 , 93, 4273-4279	19.7	16
63	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. <i>Diabetes Care</i> , 2021 , 44, 1586-1594	14.6	16
62	Brief report: depression and history of suicide attempts in adults with new-onset Type 2 Diabetes. <i>Psychoneuroendocrinology</i> , 2013 , 38, 2810-4	5	15
61	Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2016 , 44, 1312-1319	5.6	15
60	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. <i>Current Diabetes Reports</i> , 2017 , 17, 124	5.6	13
59	Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1710-1721	6.7	13
58	Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial. <i>Journal of Investigative Medicine</i> , 2014 , 62, 676-86	2.9	13
57	Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000761	4.5	13
56	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e2981	7.5	12

55	Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. <i>Clinical Diabetes</i> , 2020 , 38, 390-402	2.9	12
54	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	11
53	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. <i>Diabetologia</i> , 2020 , 63, 473-485	10.3	11
52	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 563-574	18.1	11
51	Performance of a Random Glucose Case-Finding Strategy to Detect Undiagnosed Diabetes. <i>American Journal of Preventive Medicine</i> , 2017 , 52, 710-716	6.1	10
50	Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. <i>JAMA Internal Medicine</i> , 2021 , 181, 1562-1574	11.5	10
49	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <i>Cardiovascular Diabetology</i> , 2020 , 19, 156	8.7	10
48	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , 2021 , 44, 1595-1603	14.6	10
47	SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. <i>Endocrine Practice</i> , 2017 , 23, 831-840	3.2	9
46	Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 200-205	6.7	9
45	Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. <i>Journal of Investigative Medicine</i> , 2012 , 60, 1059-63	2.9	9
44	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021 , 144, 74-84	16.7	9
43	Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience. <i>Otolaryngology - Head and Neck Surgery</i> , 2020 , 162, 634-640	5.5	7
42	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2241-2247	6.7	7
41	Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. <i>Postgraduate Medicine</i> , 2021 , 1-6	3.7	7
40	Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2177-2182	6.7	7
39	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. <i>Cardiovascular Diabetology</i> , 2019 , 18, 156	8.7	6
38	The metabolic cost of lowering blood pressure with hydrochlorothiazide. <i>Diabetology and Metabolic Syndrome</i> , 2013 , 5, 35	5.6	6

37	Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide. <i>Circulation</i> , 2018 , 137, 2200-2207	6.7	6
36	The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1454-1457	6.7	5
35	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
34	Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. <i>Diabetes Therapy</i> , 2021 , 12, 879-898	3.6	5
33	Metabolic response 4 years after gastric bypass in a complete cohort with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018 , 137, 224-230	7.4	4
32	Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes. <i>Obesity</i> , 2021 , 29, 829-836	8	4
31	Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1640-1651	6.7	4
30	Doc, I Just Ate: Interpreting Random Blood Glucose Values in Patients with Unknown Glycemic Status. <i>Journal of General Internal Medicine</i> , 2018 , 33, 142-144	4	4
29	Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1562-1569	6.7	3
28	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 315-322	8.1	3
27	Trends in the prevalence of cardiometabolic disease and cardiovascular events by body mass index category in adults from 1999 to 2016. <i>Postgraduate Medical Journal</i> , 2020 , 96, 655-659	2	3
26	Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5). <i>Canadian Journal of Diabetes</i> , 2016 , 40, S41-S42	2.1	3
25	SweetB syndrome and subacute thyroiditis: an unrecognized association?. <i>Thyroid</i> , 2010 , 20, 1425-6	6.2	3
24	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 analyses. <i>BMJ Open</i> , 2020 , 10, e037883	3	3
23	Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021 , 4, e00170	2.7	3
22	Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. <i>JAMA Network Open</i> , 2022 , 5, e2148030	10.4	3
21	A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2133-2141	6.7	2
20	Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2020 , 132, 337-345	3.7	2

19	Multilevel Variation in Diabetes Screening Within an Integrated Health System. <i>Diabetes Care</i> , 2020 , 43, 1016-1024	14.6	2
18	Impact of bariatric surgery on cerebral vascular reactivity and cognitive function: a non-randomized pilot study. <i>Pilot and Feasibility Studies</i> , 2020 , 6, 21	1.9	2
17	First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2015 , 3, 2324709615603723	1.2	2
16	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2248-2256	6.7	2
15	Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1). <i>Journal of the Endocrine Society</i> , 2021 , 5, A24-A24	9.4	2
14	An indirect treatment comparison of the efficacy of semaglutide 1.0mg versus dulaglutide 3.0 and 4.5mg. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2513-2520	6.7	2
13	Gastrointestinal tolerability of once-weekly semaglutide 2.4mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 94-105	6.7	2
12	Response to Comment on: Harrison et al. β cell function preservation after 3.5 years of intensive diabetes therapy. <i>Diabetes Care</i> 2012;35:1406-1412. <i>Diabetes Care</i> , 2013 , 36, e17	14.6	1
11	Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	1
10	Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4). <i>Journal of the Endocrine Society</i> , 2021 , 5, A7-A7	9.4	1
9	Novel Trial Design: CHIEF-HF. <i>Circulation: Heart Failure</i> , 2021 , 14, e007767	7.6	1
8	Insulin Sensitivity After Living Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2021 , 53, 1858-1864	1.1	0
7	VISUAL VIGNETTE. <i>Endocrine Practice</i> , 2019 , 25, 771	3.2	
6	Comparative Evaluation of Two Venous Sampling Techniques for the Assessment of Pancreatic Insulin and Zinc Release upon Glucose Challenge. <i>Journal of Diabetes Research</i> , 2015 , 2015, 789359	3.9	
5	The impact of bariatric surgery on cerebral vascular reactivity. <i>FASEB Journal</i> , 2018 , 32, 711.1	0.9	
4	Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care. <i>American Journal of Managed Care</i> , 2020 , 26, S344-S355	2.1	
3	Pancreatic triglyceride levels: implications for type 2 diabetes development in ethnic minorities. <i>FASEB Journal</i> , 2012 , 26, 686.20	0.9	
2	Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Using Insulin. <i>Journal of the Endocrine Society</i> , 2021 , 5, A331-A332	0.4	

- 1 Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1214-1215²⁷⁴